A Phase II Study of Pembrolizumab and High-Dose Pemetrexed for the Treatment of Patients with Progressive Chordoma
To determine objective response rate (ORR) according to RECIST v1.1 of pembrolizumab and high-dose pemetrexed in the treatment of patients with chordoma until disease progression. The OOR will be investigator assessed.
Main Inclusion/Exclusion:
- Progressive chordoma within past 6 months
- ECOG 0-1
- No chronic steroids >10 mg prednisone daily
Indications:
- Progressive Chordoma
Contact: Neuro.Research@providence.org